Most Read Articles
Rachel Soon, 29 May 2019

AstraZeneca has announced plans to invest over US$125 million (RM500 million) in Malaysia over the next 5 years, with a focus on patient-centred innovation, local talent development and new robotic and cognitive technologies.

Tristan Manalac, 29 May 2019
Beta blockers (BB) and renin-angiotensin inhibitors (RAI) effectively protect against anthracycline-induced cardiotoxicity among cancer patients, preserving left ventricular ejection fraction (LVEF) and cutting cardiac events, according to a new study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC).
Audrey Abella, 3 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.

Psychosocial disposition may affect pain after breast surgery

18 May 2019

Having a negative affect and high temporal summation of pain (TSP) appears to increase the risk of significant pain and continued opioid use after breast surgery, reports a new study.

Researchers conducted a prospective observational analysis of 234 women (mean age, 55.5±12.3 years) undergoing breast-conserving surgery or mastectomy with or without reconstruction. Participants completed a short bedside quantitative sensory testing battery and had the psychosocial characteristics measured. The brief pain inventory and cancer-specific questionnaires were used to evaluate postoperative pain.

At baseline, catastrophizing was relatively lower (mean, 5.7±6.4) while anxiety was higher (mean, 55.8±7.5) than corresponding population averages. Sleep disturbance (mean, 50.52±8.9) and depressive symptoms (mean, 48.2±7.1), on the other hand, were average.

Around 30 percent of the participants reported moderate-to-severe pain 2 weeks after the surgery. Upon adjusted analysis, baseline pain (odds ratio [OR], 1.31; 95 percent CI, 1.00–1.72; p=0.049), baseline pain interference (OR, 1.04; 1.01–1.08; p=0.011), axillary dissection (OR, 4.42; 1.69–11.54; p=0.003), behavioural coping (OR, 1.21; 1.06–1.37; p=0.005) and TSP at baseline (OR, 1.36; 1.12–1.65; p=0.002) emerged as significant predictors of moderate to severe pain.

Notably, positive affect exerted a protective effect against moderate-to-severe pain 2 weeks after surgery (OR, 0.93; 0.88–0.99; p=0.022).

In comparison, baseline pain severity (OR, 1.22; 1.02–1.46; p=0.0307), baseline opioid use (OR, 18.63; 3.11–111.62; p=0.0015), baseline TSP (OR, 1.24; 1.02–1.50; p=0.0278), depression (OR, 1.11; 1.03–1.20; p=0.0078) and axillary dissection (OR, 4.22; 1.55–1147; p=0.0050) were among the factors significantly associated with continued opioid use at 2 weeks.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 29 May 2019

AstraZeneca has announced plans to invest over US$125 million (RM500 million) in Malaysia over the next 5 years, with a focus on patient-centred innovation, local talent development and new robotic and cognitive technologies.

Tristan Manalac, 29 May 2019
Beta blockers (BB) and renin-angiotensin inhibitors (RAI) effectively protect against anthracycline-induced cardiotoxicity among cancer patients, preserving left ventricular ejection fraction (LVEF) and cutting cardiac events, according to a new study presented at the recently concluded 2019 Congress of the Asian Pacific Society of Cardiology (APSC).
Audrey Abella, 3 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.